 |
|
Topical Mitomycin Chemotherapy for Conjunctival Malignant Melanoma and Primary Acquired Melanosis With Atypia
Clinical Experience With Histopathologic Observations
Hakan Demirci, MD;
Steven A. McCormick, MD;
Paul T. Finger, MD
Arch Ophthalmol. 2000;118:885-891.
Objectives To clinically evaluate topical mitomycin chemotherapy in patients with diffuse, multifocal, or recurrent primary acquired melanosis with atypia and/or conjunctival malignant melanoma and to histopathologically study ocular tissue samples obtained before and after treatment.
Methods Chemotherapy with topical mitomycin, 0.04% 4 times daily, was administered for 28 days as the primary and only treatment in 7 patients (after biopsy) and for 7 days as adjuvant therapy to excision and cryotherapy in 5 patients. Mean follow-up was 38 months. Five patients developed subconjunctival recurrences, for which 2 underwent orbital exenteration and 3 were treated conservatively. Histopathologic specimens of conjunctival, adnexal, and ocular tissues obtained before and after chemotherapy were evaluated.
Results Regression of tumor was observed in 11 patients with primary or adjuvant topical mitomycin chemotherapy. One patient with nodular melanoma was resistant to mitomycin chemotherapy. Histopathologic findings included regionally variable conjunctival epithelial atrophy and thinning. Dyskeratosis and focal keratinization in conjunctival epithelium were noted. Epithelial nuclei were occasionally pyknotic in areas of atrophic epithelium. Subepithelial inflammation was present and was most intense in areas with severe atrophy and/or keratosis. Two patients with primary treatment and 2 with adjuvant treatment developed subconjunctival recurrence. In patients with recurrent malignant melanoma, the deeper layers of the lamina propria were involved, with sparing of the epithelium and superficial lamina propria. Transient keratoconjunctivitis was observed in all patients during treatment. In evaluation of the exenteration specimens, corneal, scleral, episcleral, retinal, and anterior structures were within normal limits.
Conclusions Topical mitomycin chemotherapy was found to induce regression of conjunctival melanoma and primary acquired melanosis with atypia. When mitomycin chemotherapy was used as an adjuvant to excision and cryotherapy, 2 (40%) of 5 patients experienced tumor recurrence at a mean of 4.3 years' follow-up. Our histopathologic findings demonstrated a long-term mitomycin chemotherapy–related effect on the conjunctiva. The degree of chronic atrophy and inflammation was not clinically significant. The pattern of effect and location of recurrent disease suggest that this regimen of topical mitomycin chemotherapy was most effective for superficial tumors. No complications that would preclude use of our dose regimen were noted. Although subconjunctival or orbital recurrences were noted, topical mitomycin chemotherapy warrants further investigation as an alternative treatment for primary acquired melanosis with atypia and conjunctival malignant melanoma.
From The New York Eye Cancer Center (Dr Finger) and the Departments of Ophthalmology and Pathology and Laboratory Medicine, The New York Eye and Ear Infirmary (Drs Demirci, McCormick, and Finger), New York.
RELATED ARTICLE
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2000;118(7):1011-1012.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical mapping of conjunctival melanomas
Damato and Coupland
Br. J. Ophthalmol. 2008;92:1545-1549.
ABSTRACT
| FULL TEXT
Whole-body 18 FDG PET/CT imaging for lymph node and metastatic staging of conjunctival melanoma
Kurli et al.
Br. J. Ophthalmol. 2008;92:479-482.
ABSTRACT
| FULL TEXT
Topical mitomycin chemotherapy for malignant conjunctival and corneal neoplasia
Finger
Br. J. Ophthalmol. 2006;90:807-809.
FULL TEXT
Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia
Khong and Muecke
Br. J. Ophthalmol. 2006;90:819-822.
ABSTRACT
| FULL TEXT
CASE 4. A Black Eye: Melanoma In Situ of the Conjunctiva
Kyto and Kivela
JCO 2006;24:1013-1014.
FULL TEXT
Population-Based Assessment of Clinical Characteristics Predicting Outcome of Conjunctival Melanoma in Whites
Tuomaala et al.
IOVS 2002;43:3399-3408.
ABSTRACT
| FULL TEXT
Dramatic regression of conjunctival and corneal acquired melanosis with topical mitomycin C
Shields et al.
Br. J. Ophthalmol. 2002;86:244-245.
FULL TEXT
Preoperative topical and intraoperative local mitomycin C adjuvant therapy in the management of ocular surface neoplasias
Kemp et al.
Br. J. Ophthalmol. 2002;86:31-34.
ABSTRACT
| FULL TEXT
Impression cytology following mitomycin C therapy for ocular surface squamous neoplasia
McKelvie and Daniell
Br. J. Ophthalmol. 2001;85:1115-1119.
ABSTRACT
| FULL TEXT
Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia
Paridaens et al.
Br. J. Ophthalmol. 2001;85:658-661.
ABSTRACT
| FULL TEXT
|
